YUPELRI approved by China's NMPA as the first once-daily nebulized LAMA for maintenance treatment of COPD Approval triggers $7.5 million milestone payment from Viatris, with eligibility to receive further sales milestones and tiered royalties on net sales in China Theravance Biopharma incurs no commercial costs in China ; Viatris is responsible for the launch and commercialization DUBLIN , June 26, 2025 /PRNewswire/ --... Read More

Definitive agreement to result in one-time $225 million cash payment Theravance Biopharma retains rights to up to $150 million in milestones from Royalty Pharma on Trelegy Ellipta net sales in 2025 and 2026, requiring minimal to no growth over 2024 actuals to be achieved $225 million from royalty transaction announced today, in addition to the $1.1 billion upfront received in 2022, and up to $200 million in milestones (of... Read More

DUBLIN , May 13, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a Fireside Chat at the H.C. Wainwright 3 rd Annual BioConnect Investor Conference in New York City at NASDAQ Tuesday, May 20 at 10:30 AM EDT ( 7:30 AM PDT / 3:30 PM IST ) and will be hosting in-person meetings with the investment community at the conference. A webcast of the event may be accessed by visiting Theravance.com ,... Read More

DUBLIN , May 9, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced presentation of analyses of its previous Phase 3 program evaluating ampreloxetine, an investigational medicine for the treatment of symptomatic neurogenic orthostatic hypotension (nOH) at the International MSA Congress, taking place May 9-11 in Boston, Massachusetts . A subgroup analysis... Read More

YUPELRI ® (revefenacin) net sales of $58.3 million , recognized by Viatris, increased 6% versus Q1 2024 1 TRELEGY net sales of $854M , as reported by GSK, increased 14% versus Q1 2024 2 CYPRESS study open label enrollment nearing completion with final patient expected to be enrolled by late summer Quarter-end cash balance of $131 million , with no debt Reaffirming all financial guidance metrics DUBLIN , May 8, 2025... Read More

DUBLIN , April 28, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced that analyses of the initial Phase 3 program of ampreloxetine (Studies 169 and 170) will be presented at the International MSA Congress, taking place May 9-11, 2025 , in Boston , Massachusetts. These analyses support the Company's understanding of ampreloxetine's highly selective... Read More

DUBLIN , April 24, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its first quarter 2025 financial results and provide a business update after market close on Thursday, May 8, 2025 . An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm EDT ( 2:00 pm PDT / 10:00 pm IST ) that day. Conference Call Information To participate in the live call by telephone, please dial... Read More

Analyses from Randomized Controlled Trials Further Support the Target Engagement and Safety Profile of Ampreloxetine in Neurodegenerative Disease DUBLIN , April 7, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced new analyses from its previous Phase 3 program evaluating ampreloxetine, an investigational medicine for the treatment of symptomatic... Read More

DUBLIN , March 31, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a fireside chat at the Jones Healthcare and Technology Innovation Conference in Las Vegas on Wednesday, April 9 at 11:30 am PDT ( 2:30 pm EDT / 6:30 PM GMT ). Members of Theravance Biopharma senior management will also be hosting one-on-one meetings at the conference. To attend the fireside chat and schedule meetings with... Read More

DUBLIN , March 27, 2025 /PRNewswire/ -- Theravance Biopharma, Inc . ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced new analyses of the initial Phase 3 program of ampreloxetine (Studies 169 and 170) supporting its selective and differentiated pharmacodynamic profile will be presented at the 77th Annual Meeting of the American Academy of Neurology (AAN) Meeting, taking place April 5-9, 2025 , in San... Read More

YUPELRI ® (revefenacin) US net sales, recognized by Viatris, reached an all-time high of $66.7 million in Q4 2024 and $238.6 million in FY 2024, up 10% and 8%, respectively, compared with 2023 1 FY 2024 TRELEGY Net Sales, as reported by GSK, of $3.46 billion , up 26% compared with 2023 and triggering a $50 million milestone to Theravance Biopharma 2 , 3 CYPRESS study on track to enroll final patient in the open label portion... Read More

DUBLIN , Feb. 20, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will present at the TD Cowen 45 th Annual Health Care Conference on Tuesday, March 4 at 11:50 am EST ( 8:50 am PST / 4:50 pm GMT ) and will be hosting in-person meetings with the investment community at the conference. Webcast of the event may be accessed by visiting Theravance.com , under the Investors section, Events and Presentations. Replay... Read More

DUBLIN, Ireland , Feb. 12, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its fourth quarter and full year 2024 financial results and provide a business update after market close on Wednesday, February 26, 2025 . An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm EST ( 2:00 pm PST / 10:00 pm GMT ) that day. Conference Call Information To participate in the live call... Read More

DUBLIN , Feb. 5, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will present at the Oppenheimer 35 th Annual Healthcare Life Sciences Conference on Wednesday, February 12 at 12:00 pm EST ( 9:00 am PST / 5:00 pm GMT ). Webcast of the event may be accessed by visiting Theravance.com , under the Investors section, Events and Presentations. Replay of the webcast will be archived on the Company's website for 30... Read More

DUBLIN , Dec. 17, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced that members of its management team will hold investor meetings during the 43rd Annual J.P. Morgan Healthcare Conference, January 13-16, 2025 , in San Francisco, CA. To request a one-on-one meeting with the Theravance Biopharma management team, please contact us at... Read More

DUBLIN , Nov. 20, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a Fireside Chat at the 7 th Annual Evercore HealthCONx Conference on Tuesday, December 3 at 11:15 am EST ( 8:15 am PST / 4:15 pm GMT ) and will be hosting in-person meetings with the investment community at the conference. Webcast of the event may be accessed by visiting Theravance.com , under the Investors section, Events... Read More

Third quarter results highlight strong operational performance across key value drivers: YUPELRI ® (revefenacin) net sales of $62.2 million , recognized by Viatris, an all-time high, increased 7% versus Q3 2023 and 14% versus Q2 2024 1 CYPRESS enrollment in-line with expectations, with timelines on track TRELEGY net sales increased 17%, to $789 million , as reported by GSK: Q4 sales of at least ~$260 million needed to earn... Read More

DUBLIN , Oct. 24, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its third quarter 2024 financial results and provide a business update after market close on Tuesday, November 12, 2024 . An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm EST ( 2:00 pm PST / 10:00 pm GMT ) that day. Conference Call Information To participate in the live call by telephone, please... Read More

DUBLIN , Oct. 18, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced the publication of a sub-study of the pivotal 12-week, randomized, registrational revefenacin Phase 3 trials (Trials 0126 [ NCT02459080 ] and 0127 [ NCT02512510 ]) for YUPELRI, the first and only FDA approved once-daily nebulized long-acting muscarinic antagonist (LAMA), evaluating the... Read More

DUBLIN , Aug. 27, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference in New York City on Tuesday, September 10 at 10:00 am ET ( 7:00 am PT / 3:00 pm IST ) and will be hosting in-person meetings with the investment community at the conference. Webcast of the event may be accessed by visiting Theravance.com , under... Read More

Q2 2024 YUPELRI ® (revefenacin) net sales of $54.5 million , recognized by Viatris, decreased 1% from Q2 2023 1 Viatris collaboration revenue of $14.3 million , increased 4% versus Q2 2023 Partner Viatris submitted YUPELRI NDA in China ; $7.5 million milestone if approved Now expecting last patient into the open label portion of CYPRESS in mid-2025, top line data anticipated approximately 6 months later Q2 2024 TRELEGY net... Read More

DUBLIN , July 25, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Tuesday, August 6 at 12:00 pm ET ( 9:00 am PT / 5:00 pm IST ). Members of Theravance Biopharma senior management will also be hosting one-on-one meetings at the conference. To listen to the webcast or schedule meetings with management, please contact your BTIG... Read More

DUBLIN , July 22, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its second quarter 2024 financial results and provide a business update after market close on Monday, August 5, 2024 . An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm ET ( 2:00 pm PT / 10:00 pm IST ) that day. Conference Call Information To participate in the live call by telephone, please... Read More

Q1 2024 YUPELRI ® (revefenacin) net sales of $55.2 million , recognized by Viatris, increased 18% from Q1 2023 1 Viatris collaboration revenue of $14.5 million , increased 39% versus Q1 2023, reflecting margin improvement Continued progress for ampreloxetine CYPRESS enrollment Virtual ampreloxetine KOL event scheduled for May 23, 2024 Q1 2024 ending cash balance of $100 million DUBLIN , May 13, 2024 /PRNewswire/ --... Read More

DUBLIN , May 9, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a Fireside Chat at the H.C. Wainwright 2 nd Annual BioConnect Investor Conference at NASDAQ Monday, May 20 at 11:30 AM EDT ( 8:30 AM PDT / 4:30 PM IST ) and will be hosting in-person meetings with the investment community at the conference. Webcast of the event may be accessed by visiting Theravance.com , under the Investors... Read More

DUBLIN , April 29, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its first quarter 2024 financial results and provide a business update after market close on Monday, May 13, 2024 . An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm ET ( 2:00 pm PT / 10:00 pm IST ) that day. Conference Call Information To participate in the live call by telephone, please... Read More

DUBLIN , April 10, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (the "Company") (NASDAQ: TBPH) today announced it will host a virtual KOL event on Thursday, May 23, 2024 from 10:00 AM to 11:30 AM ET , featuring Horacio Kaufmann , MD, FAAN (Felicia B. Axelrod Professor of Neurology and Professor of Medicine at New York University Grossman School of Medicine) and Italo Biaggioni, MD (Professor of Medicine and Pharmacology... Read More

Q4 2023 YUPELRI ® (revefenacin) net sales, recognized by Viatris, increased 9% from Q4 2022, reaching an all-time high of $60.6 million 1 Full Year 2023 Viatris Collaboration Revenue increased 18% to $57.2 million GAAP Net Loss of $8.5 million in Q4; Achieved goal of profitability on Non-GAAP basis in Q4, with Non-GAAP Net Profit of $1.4 million 2 Completed $325 million capital return program, reducing shares outstanding by... Read More

DUBLIN , Feb. 22, 2024 /PRNewswire/ -- Theravance Biopharma, Inc . (NASDAQ: TBPH) will participate in the CNS Corporate Panel Discussion at the TD Cowen 44th Annual Health Care Conference in Boston, MA on Tuesday, March 5 at 10:30 am ET ( 7:30 am PT / 3:30 pm GMT ). Members of Theravance Biopharma senior management will be hosting one on one meetings at the conference. Webcast of the event may be accessed by visiting... Read More

DUBLIN , Feb. 14, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its fourth quarter and full year 2023 financial results and provide a business update after market close on Monday, February 26, 2024 . An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm ET ( 2:00 pm PT / 10:00 pm GMT ) that day. Conference Call Information To participate in the live call by telephone,... Read More

DUBLIN , Jan. 5, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced results from the Phase 4 PIFR-2 study of YUPELRI ® (revefenacin) inhalation solution, the only once-daily, nebulized long-acting muscarinic antagonist (LAMA) approved in the U.S. for maintenance treatment of COPD. The PIFR-2 study aimed to demonstrate greater improvement in lung function for YUPELRI delivered via standard jet... Read More

Enters into Cooperation Agreement with Shareholder Irenic Capital Reaffirms Intention to Return All Excess Capital to Shareholders and Maximize Shareholder Value DUBLIN , Dec. 21, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance" or the "Company") (NASDAQ: TBPH) today announced the appointment to its Board of Directors of Jeremy Grant , who serves as a Special Advisor to Irenic Capital Management LP ("Irenic").... Read More

DUBLIN , Dec. 18, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced that members of its management team including Rick E Winningham, CEO, and Aziz Sawaf , CFO, will hold investor meetings during the 42 nd Annual J.P. Morgan Healthcare Conference, January 8-11, 2024 , in San Francisco, CA. To request a one-on-one meeting with the Theravance Biopharma... Read More

DUBLIN , Nov. 16, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced that a new, anchor-based analysis of ampreloxetine data in neurogenic orthostatic hypotension (nOH) will be presented at the 34 th International Symposium on The Autonomic Nervous System, a meeting of the American Autonomic Society (AAS), taking place November 15-18, 2023 , in Rio Grande,... Read More

DUBLIN , Nov. 15, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a Fireside Chat at the 6 th Annual Evercore ISI HealthCONx Conference Tuesday, November 28 at 1:45 pm EST ( 10:45 am PST / 6:45 pm GMT ) and will be hosting in-person meetings with the investment community at the conference. A Webcast of the event may be accessed by visiting www,Theravance.com, under the Investors section:... Read More

Q3 2023 YUPELRI ® (revefenacin) net sales, recognized by Viatris, increased 9% from Q3 2022, reaching an all-time high of $58.3 million 1 Progress made towards the achievement of non-GAAP profitability, with Q3 2023 GAAP Net Loss of $9.0 million and Non-GAAP Loss of $0.7 million 2 Company expects to complete $325 million capital return program by year-end, having returned $30.8 million via share repurchases during Q3 2023... Read More

DUBLIN , Oct. 19, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its third quarter 2023 financial results and provide a business update after market close on Tuesday, November 7, 2023 . An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm ET ( 2:00 pm PT / 10:00 pm GMT ) that day. Conference Call Information To participate in the live call by telephone, please... Read More

DUBLIN , Aug. 29, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a Fireside Chat at the H.C. Wainwright 25 th Annual Global Investment Conference on Tuesday, September 12 at 9:30 am ET ( 6:30 am PT / 2:30 pm IST ) and will be hosting in-person meetings with the investment community at the conference. A Webcast of the event may be accessed by visiting Theravance.com, under the Investors... Read More

DUBLIN , Aug. 28, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced new ampreloxetine data in neurogenic orthostatic hypotension (nOH) will be presented at the 2023 International Congress of Parkinson's Disease and Movement Disorders (MDS), taking place August 27-31, 2023 , in Copenhagen, Denmark . "The data presented at this meeting continue to support... Read More

Q2 2023 YUPELRI ® (revefenacin) net sales of $55.0 million , recognized by Viatris, up 12% from Q2 2022 1 Q2 2023 YUPELRI total retail TRx and new to product TRx again reached all-time highs, up 26% and 53%, Y/Y, respectively 2 PIFR-2 enrollment nearing completion; top-line data in late Q4 2023, with disclosure anticipated in January 2024 Company expects to complete $325 million capital return program by year-end, having... Read More

DUBLIN , July 24, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its second quarter 2023 financial results and provide a business update after market close on Monday, August 7, 2023 . An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm ET ( 2:00 pm PT / 10:00 pm IST ) that day. Conference Call Information To participate in the live call by telephone, please... Read More

DUBLIN , May 9, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) status to ampreloxetine for the treatment of symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA). MSA is a rare neurodegenerative disorder in which... Read More

Q1 2023 YUPELRI ® (revefenacin) net sales of $47.0 million , recognized by Viatris, up 8% from Q1 2022 1 Q1 2023 YUPELRI retail new patient starts and total prescriptions up 61% and 29%, respectively, year-over-year, reaching all-time highs 2 CYPRESS Phase 3 study of ampreloxetine recruiting; anticipate completing enrollment during H2 2024 On track to complete $325 million capital return program by year-end; completed $215... Read More

DUBLIN , April 24, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its first quarter 2023 financial results and provide a business update after market close on Monday, May 8, 2023 . An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm ET ( 2:00 pm PT / 10:00 pm IST ) that day. Conference Call Information To participate in the live call by telephone, please pre-register... Read More

DUBLIN , April 11, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced the appointment of Jim Kelly , Managing Director at Weiss Asset Management, the Company's second largest shareholder, to its Board of Directors. With the appointment of Mr. Kelly, four new directors have joined the Company's Board of Directors since 2018 as part of its ongoing board... Read More

DUBLIN , April 10, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will present at the 22 nd Annual Needham Virtual Healthcare Conference on Monday, April 17 at 3:45 pm ET ( 12:45 pm PT / 8:45 pm IST ). Webcast of the event may be accessed by visiting Theravance.com, under the Investors section, Presentations and Events. Replay of the webcast will be archived on the Company's website for 30 days. About... Read More

DUBLIN , March 2, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in the Respiratory/Infections Corporate Panel Discussion at the 43 rd Annual TD Cowen Health Care Conference on Wednesday, March 8 at 10:30 am ET ( 7:30 am PT / 3:30 pm GMT ). Webcast of the event may be accessed by visiting Theravance.com, under the Investors section, Presentations and Events. Replay of the webcast will be... Read More

Increases capital return program to $325 million from $250 million ; as of 2/27/23, approximately $170 million remains in the program Discontinuing investments in research, reducing headcount by approximately 17% Reports highest quarter of YUPELRI ® (revefenacin) net sales and profitability to date; $19.5 million Q4 2022 sales up 27% from Q4 2021 (TBPH implied 35% share) 1 On track to begin enrollment in ampreloxetine Phase... Read More

DUBLIN , Feb. 21, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its fourth quarter and full year 2022 financial results and provide a business update after market close on Monday, February 27, 2023 . An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm ET ( 2:00 pm PT / 10:00 pm GMT ) that day. Conference Call Information To participate in the live call by telephone,... Read More

DUBLIN , Feb. 9, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a Fireside Chat at the SVB Securities Global Biopharma Conference on Wednesday, February 15 at 8:00 am ET ( 5:00 am PT / 1:00 pm GMT ). Webcast of the event may be accessed by visiting www.Theravance.com , under the Investors section, Presentations and Events. Replay of the webcast will be archived on the Company's website for... Read More

Strategic priorities focused on continued Net Sales growth for YUPELRI ® (revefenacin) and conduct of the ampreloxetine Phase 3 study (CYPRESS) in Multiple System Atrophy (MSA) patients with symptomatic neurogenic orthostatic hypotension (nOH) Initiate CYPRESS study in Q1 2023 and submit orphan drug designation in early 2023 Complete PIFR-2 study for YUPELRI ® in 2H 2023 Execute $250 million return of capital program, of... Read More

DUBLIN , Nov. 22, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced the final results of its Dutch auction tender offer (the "Offer") to purchase up to $95 million of its ordinary shares, par value $0.00001 per share (the "Shares"), which expired at midnight, New York City time, at the end of the day on November 17, 2022 . Based on the final count by... Read More